Company has initiated a process to explore and review strategic options focused on maximizing shareholder value
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Dec. 17, 2024 /CNW/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company that, prior to the discontinuation of its clinical trials and preclinical and other development programs, has been focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fourth quarter and fiscal year ended September 30, 2024.
"We recently made the difficult decision to terminate the clinical development of masofaniten, and withdraw the related IND and CTAs, based on an interim analysis of the data from the Phase 2 combination study, concluding that masofaniten combined with enzalutamide was unlikely to meet its primary endpoint," said David Parkinson, MD, President and CEO of ESSA. "We are currently evaluating and reviewing our strategic options focused on maximizing shareholder value and look forward to providing further updates in the near future."
Fourth Quarter Fiscal 2024 and Recent Updates
Summary Financial Results
(Amounts expressed in U.S. dollars)
Liquidity and Outstanding Share Capital
About ESSA Pharma Inc.
ESSA is a clinical-stage pharmaceutical company that was previously focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit www.essapharma.com.
Forward-Looking Statement Disclaimer
This release contains certain information which, as presented, constitutes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities laws (collectively, "forward-looking statements"). Forward-looking statements include, but are not limited to, statements that relate to future events and often addresses expected future business and financial performance, containing words such as "anticipate", "believe", "plan", "estimate", "expect", and "intend", statements that an action or event "may", "might", "could", "should", or "will" be taken or occur, or other similar expressions and includes, but is not limited to, statements regarding the termination of the Company's clinical studies of masofaniten, the Company's financial resources, the evaluation of the Company's strategic alternatives, the primary and PSA-related endpoints of the Phase 2 study and other statements surrounding the Company's evaluation of masofaniten.
Forward-looking statements are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of ESSA to control or predict, and which may cause ESSA's actual results, performance or achievements to be materially different from those expressed or implied thereby. Such statements reflect ESSA's current views with respect to future events, are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by ESSA as of the date of such statements, are inherently subject to significant medical, scientific, business, economic, competitive, political and social uncertainties and contingencies. In making forward looking statements, ESSA may make various material assumptions, including but not limited to (i) the accuracy of ESSA's financial projections; (ii) obtaining positive results of clinical trials; (iii) obtaining necessary regulatory approvals; (iv) that one or more strategic options may be available to the Company at reasonably acceptable terms; and (v) general business, market and economic conditions.
Forward-looking statements are developed based on assumptions about such risks, uncertainties and other factors set out herein and in ESSA's Annual Report on Form 10-K dated December [10], 2024, under the heading "Risk Factors", a copy of which is available on ESSA's profile on EDGAR at www.sec.gov and on SEDAR+ at www.sedarplus.ca, and as otherwise disclosed from time to time on ESSA's EDGAR and SEDAR+ profiles. Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements are made and ESSA undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as may be required by applicable United States and Canadian securities laws. Readers are cautioned against attributing undue certainty to forward-looking statements.
Contacts
ESSA Pharma Inc.
David Wood, Chief Financial Officer
778.331.0962
dwood@essapharma.com
Investors and Media
Argot Partners
212.600.1902
essa@argotpartners.com
ESSA PHARMA INC.
CONSOLIDATED BALANCE SHEETS
Amounts in thousands of United States dollars
September 30, | September 30, | |
Cash | $ 103,710 | $ 33,702 |
Prepaids and other assets | 24,402 | 115,420 |
Total assets | $ 128,112 | $ 149,122 |
Current liabilities | 3,301 | 3,495 |
Long-term lease liability | 205 | - |
Shareholders' deficiency | 124,606 | 145,627 |
Total liabilities and shareholders' equity | $ 128,112 | $ 149,122 |
ESSA PHARMA INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Amounts in thousands of United States dollars, except share and per share data
Three months September 30, | Three months September 30, | Year ended September 30, | Year ended September 30, | ||||
OPERATING EXPENSES | |||||||
Research and development | $ 4,188 | $ 5,226 | $ 21,207 | $ 21,323 | |||
Financing costs | - | 1 | - | 7 | |||
General and administration | 3,507 | 1,922 | 13,214 | 10,812 | |||
Total operating expenses | (7,695) | (7,149) | (34,421) | (32,142) | |||
Interest and other items | 1,339 | 1,668 | 5,878 | 5,560 | |||
Net loss before taxes | (6,356) | (5,481) | (28,543) | (26,582) | |||
Income tax expense (recovery) | — | — | - | (2) | |||
Net loss for the period | $ (6,356) | $ (5,483) | $ (28,543) | $ (26,584) | |||
OTHER COMPREHENSIVE LOSS | |||||||
Unrealized gain (loss) on short- | 37 | 2 | 57 | 15 | |||
Loss and comprehensive loss for | $ (6,319) | $ (5,479) | $ (28,486) | $ (26,569) | |||
Basic and diluted loss per | $ (0.14) | $ (0.12) | $ (0.64) | $ (0.60) | |||
Weighted average number of common shares outstanding | 44,366,126 | 44,092,374 | 44,277,050 | 44,089,557 | |||
SOURCE ESSA Pharma Inc